Peter Öhlschläger

Title: The Innovations of Peter Öhlschläger

Introduction

Peter Öhlschläger is a notable inventor based in Constance, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of immunological adjuvants. His work focuses on enhancing vaccine efficacy through innovative approaches.

Latest Patents

Peter Öhlschläger holds a patent for "Recombinant protein bodies as immunogen-specific adjuvants." This patent describes an adjuvant comprised of particulate recombinant protein body-like assemblies (RPBLAs). These assemblies contain a recombinant fusion protein that includes a protein body-inducing sequence (PBIS) and a T-cell stimulating immunogenic polypeptide. The adjuvant is designed to be used as an inoculum in host animals without prior priming vaccination, ensuring that it does not induce production of antibodies or T cell activation to the pathogenic sequence.

Career Highlights

Peter Öhlschläger is currently associated with Era Biotech, S.A., where he continues to advance his research and development efforts. His innovative work has positioned him as a key figure in the biotechnology sector, contributing to the development of more effective vaccines.

Collaborations

Peter collaborates with esteemed colleagues such as Edward Peter Rybicki and Ann Elizabeth Meyers. These partnerships enhance the research and development process, fostering innovation in the field.

Conclusion

Peter Öhlschläger's contributions to biotechnology, particularly through his patented adjuvant technology, highlight his role as an influential inventor. His work continues to pave the way for advancements in vaccine development and immunology.